PIII Begin Period Cash Flow from 2010 to 2024

PIII Stock  USD 0.19  0.01  5.00%   
P3 Health's Begin Period Cash Flow is increasing with slightly volatile movements from year to year. Begin Period Cash Flow is predicted to flatten to about 17.4 M. Begin Period Cash Flow is the amount of cash P3 Health Partners has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities. View All Fundamentals
 
Begin Period Cash Flow  
First Reported
2010-12-31
Previous Quarter
18.5 M
Current Value
17.4 M
Quarterly Volatility
12.7 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check P3 Health financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among P3 Health's main balance sheet or income statement drivers, such as Depreciation And Amortization of 91 M, Interest Expense of 16.8 M or Selling General Administrative of 87.6 M, as well as many indicators such as Price To Sales Ratio of 0.0932, Dividend Yield of 0.0 or PTB Ratio of 0.83. PIII financial statements analysis is a perfect complement when working with P3 Health Valuation or Volatility modules.
  
Check out the analysis of P3 Health Correlation against competitors.

Latest P3 Health's Begin Period Cash Flow Growth Pattern

Below is the plot of the Begin Period Cash Flow of P3 Health Partners over the last few years. It is the amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities. P3 Health's Begin Period Cash Flow historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in P3 Health's overall financial position and show how it may be relating to other accounts over time.
Begin Period Cash Flow10 Years Trend
Slightly volatile
   Begin Period Cash Flow   
       Timeline  

PIII Begin Period Cash Flow Regression Statistics

Arithmetic Mean8,556,339
Geometric Mean3,242,899
Coefficient Of Variation148.44
Mean Deviation9,923,758
Median2,013,579
Standard Deviation12,700,929
Sample Variance161.3T
Range39.8M
R-Value0.55
Mean Square Error120.5T
R-Squared0.31
Significance0.03
Slope1,571,372
Total Sum of Squares2258.4T

PIII Begin Period Cash Flow History

202417.4 M
202318.5 M
2022140.8 K
202139.9 M
202032.9 M
20191.4 M

About P3 Health Financial Statements

Investors use fundamental indicators, such as P3 Health's Begin Period Cash Flow, to determine how well the company is positioned to perform in the future. Although P3 Health's investors may analyze each financial statement separately, they are all interrelated. Understanding these patterns can help investors make the right trading decisions.
Last ReportedProjected for Next Year
Begin Period Cash Flow18.5 M17.4 M

Currently Active Assets on Macroaxis

When determining whether P3 Health Partners is a strong investment it is important to analyze P3 Health's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact P3 Health's future performance. For an informed investment choice regarding PIII Stock, refer to the following important reports:
Check out the analysis of P3 Health Correlation against competitors.
You can also try the Investing Opportunities module to build portfolios using our predefined set of ideas and optimize them against your investing preferences.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of P3 Health. If investors know PIII will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about P3 Health listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.86)
Revenue Per Share
11.552
Quarterly Revenue Growth
0.152
Return On Assets
(0.12)
Return On Equity
(0.41)
The market value of P3 Health Partners is measured differently than its book value, which is the value of PIII that is recorded on the company's balance sheet. Investors also form their own opinion of P3 Health's value that differs from its market value or its book value, called intrinsic value, which is P3 Health's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because P3 Health's market value can be influenced by many factors that don't directly affect P3 Health's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between P3 Health's value and its price as these two are different measures arrived at by different means. Investors typically determine if P3 Health is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, P3 Health's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.